1. Home
  2. BCHT vs JSPR Comparison

BCHT vs JSPR Comparison

Compare BCHT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birchtech Corp. Common Stock

BCHT

Birchtech Corp. Common Stock

N/A

Current Price

$0.97

Market Cap

28.9M

Sector

Industrials

ML Signal

N/A

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

N/A

Current Price

$11.52

Market Cap

26.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCHT
JSPR
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.9M
26.3M
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
BCHT
JSPR
Price
$0.97
$11.52
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $249.83
AVG Volume (30 Days)
57.5K
★ 257.9K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 19.22
EPS
★ N/A
N/A
Revenue
★ $17,626,366.00
N/A
Revenue This Year
$4.39
N/A
Revenue Next Year
$45.11
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 1.26
N/A
52 Week Low
$0.97
$0.32
52 Week High
$2.59
$17.03

Technical Indicators

Market Signals
Indicator
BCHT
JSPR
Relative Strength Index (RSI) 33.08 62.78
Support Level N/A $0.64
Resistance Level $1.51 $17.03
Average True Range (ATR) 0.13 1.49
MACD -0.00 0.21
Stochastic Oscillator 0.03 61.42

Price Performance

Historical Comparison
BCHT
JSPR

About BCHT Birchtech Corp. Common Stock

Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: